William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics price target lowered to $1.50 from $4 at RBC Capital
- Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles
- Applied Therapeutics appoints Johnson as Executive Chairman, CEO steps down
- Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
- Edgewise should be bought on weakness as ARCH not likely FDA focus, says Truist